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Background and aim: Despite the high prevalence of uterine leiomyoma, according to recent 
review studies there is uncertainty and a paucity of information regarding its predisposing or 
protective factors. The aim of this study was to assess the possible association between men-
strual cycle pattern and occurrence of surgically treated myomas and also to check if depo-
medroxyprogesterone acetate (DMPA) injection earlier in reproductive life can affect the later 
occurrence of myomas needing surgical treatment.
Methods: In a case–control study in Ardabil, 85 women with definite diagnosis of surgically 
treated uterine leiomyoma and 154 community controls were enrolled. Possible predictors of 
myoma including menstrual cycle and menstrual bleeding patterns were assessed. Data were 
analyzed using SPSS software (SPSS, IBM, Somers, NY). Odds ratios were used as the main 
statistic in assessing the strength of observed associations.
Results: Mean age of the participants was 41.8 ± 8.5 years. Length of menstrual cycle was 
associated with myoma and a higher likelihood of myoma was observed among those having 
shorter menstrual cycles (P , 0.05). Number of menstrual bleeding days was also associated 
with surgically treated myoma and longer bleeding periods increased the likelihood of myoma 
(P , 0.05). Only one of the eight women who had a history of depo-medroxyprogesterone 
acetate injections had developed surgically treated uterine leiomyoma and the others belonged 
to the control group without a history of surgical treatment for uterine leiomyoma.
Conclusion: Menstrual cycle pattern is associated with developing leiomyomas requiring sur-
gical treatment. DMPA, other than its role in myoma treatment, is also assumed to have a role 
in preventing myomas, but due to the small sample size in this study, larger scale prospective 
trials are needed in the future.
Keywords: myoma, uterine leiomyoma, DMPA, medroxyprogesterone, menstrual cycle, 
  menstrual, depo-provera
Introduction
Uterine leiomyoma is the most common benign tumor of the uterus, and the most 
common female genital neoplasm. It affects 30% of all women of reproductive 
age.1,2 Although uterine leiomyoma is a very common condition it has not received 
adequate attention from researchers, possibly due to being benign. However, uterine 
leiomyoma research has been underfunded even compared with other nonmalignant 
diseases. This may be because it is usually an asymptomatic condition.3 The lack 
of research attention to uterine leiomyomas affects all aspects of the condition, but 
this is more profound regarding etiologic studies rather than therapeutic research. 
There is some evidence regarding its etiology but the literature regarding uterine 
leiomyoma risk factors should be interpreted with caution. This is due to the paucity International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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of studies   available, the   heterogeneity of populations, and 
the   conflicting results, which suggest that other unexamined 
factors may be involved.2 Several predisposing factors or 
predictors of uterine leiomyoma have been identified, includ-
ing age, endogenic and exogenic hormonal factors, African-
American ethnicity, nulliparity, diet, smoking, and obesity.2,4 
Hormonal factors or hormone-related factors have been 
controversially discussed in some cases but insufficient evi-
dence is available to support any scientific conclusions. Two 
main hormone-related predictors that have not been assessed 
for their role in predicting myomas are menstrual pattern 
and use of depo-medroxyprogesterone- acetate(DMPA).4–8 
The use of DMPA as an FDA-approved contraceptive is too 
recent to expect adequate research on its predictive role for 
uterine leiomyoma. However, the paucity of evidence on the 
role of menstrual pattern in predicting myomas is attributable 
to the neglect of this area of reproductive health research, as 
discussed above. DPMA, due to its menstrual side effects, 
is not popular as a long-term contraceptive, but it has been 
used quite widely over a period of time in Iran, particularly 
in Ardabil province.9
The aim of this study was to assess whether menstrual 
pattern can predict the occurrence of surgically treated uter-
ine myomas. A secondary objective in this research was to 
check whether DMPA injection earlier in reproductive life 
influences the occurrence of surgically treated myomas.
Methods
In a case–control study in Ardabil in 2006, 85 women with 
definite diagnosis of surgically treated uterine leiomyoma, 
along with 154 community controls, were enrolled. Cases 
were surgically treated leiomyomas undergoing surgery 
in Ardabil medical centers, with a proven pathology of 
  leiomyoma. Cases were identified by reviewing laboratory 
and hospital records from medical centers in Ardabil. A ques-
tionnaire assessing possible predictors of uterine leiomyomas, 
including menstrual cycle and menstrual bleeding pattern, was 
completed for all participants. The addresses of patients were 
obtained, and their health and contraceptive records, avail-
able in each of the 30 primary health care centers in Ardabil, 
were reviewed. About double the number of controls was 
identified for the number of cases in each center, half of them 
being neighbor controls and others chosen based on a random 
sample of the eligible population covered by each center. 
Controls included healthy women lacking a known history of 
uterine leiomyoma or diseases related to leiomyoma.
Data were entered into the computer and analyzed using 
the SPSS statistical software package (v 13; SPSS IBM, 
Somers, NY). Odds ratios were used as the main statistic in 
assessing the associations.
The study protocol was approved by the committee of 
ethics at Ardabil University of Medical Sciences. In both 
groups, informed consent was obtained before enrollment 
into the study.
Results
Mean age of the participants was 41.8 (±8.5) years. Thirty-
two of the participants were rural residents. No association 
was explored between myoma and background variables 
including literacy, occupation, age at first marriage, age at first 
delivery, and age at last delivery. Parity, gravidity, history of 
abortion, and history of cesarean section didn’t have a sta-
tistically significant difference between the case and control 
groups. Comparison of some background variables between 
case and control group participants is given in Table 1.
The median number of myomas was one lesion per 
participant, but some had multiple myomas. The largest 
myoma was 127 × 116 × 90 mm in size. Nearly two-thirds 
of the surgeries were hysterectomies while the remainder 
had undergone myomectomies.
The mean length of menstrual cycle among all participants 
was 27.9 ± 5.9 days. Mean menstruation bleeding length was 
6.1 ± 3.6 days. Mean length of menstrual cycle among cases 
and controls were 26.7 ± 5 and 28.5 ± 6.4 days respectively. 
Mean menstruation bleeding length was 6.9 ± 5.4 days for the 
case group and 5.6 ± 3.6 days for the control group, respec-
tively. Length of menstrual cycle was associated with myoma 
and a higher likelihood of myoma was observed among those 
having shorter menstrual cycles (P , 0.05). Number of 
menstrual bleeding days was also associated with surgically 
treated myoma and a longer bleeding period increased the 
likelihood of myoma (P , 0.05). As an   exploratory bivariate 
Table  1  comparison  of  some  background  variables  between 
case and control group participants
Case Control Statistical  
significance
Mean years of  
successful education
6.64   5.59 ns
Mean age at first  
delivery
19.2 18.8 ns
Mean age at last  
delivery
30.3 31.2 ns
Mean age at first  
marriage
17.5 16.8 ns
Mean gravidity 5   5.2 ns
Mean parity 4.5   4.6 ns
Abbreviation: NS, No statistically significant difference.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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analysis, the odds ratios of myoma for different cutoff levels 
of menstrual cycle length are given in Table 2 along with 
their 95% confidence intervals.
Myoma was more likely among menopausal women 
(P , 0.01). Among myoma cases, 18.5% were menopausal 
while this figure was 3.5% for the control group. A history 
of infertility, tubectomy, number of live births, and time after 
last delivery were not found to be associated with myoma. 
History of menometrorrhagia increased the odds of myoma 
by 3.1 times (95% CI: 1.5–6.8).
Among the participants, eight women had used DMPA 
injection as a contraceptive during the 10 years before the 
interview. Only one case of these had developed myoma 
and the others belonged to the control group without surgi-
cally treated myomas. The low expected count violated the 
assumption to use chi-square test and Fisher’s exact test 
didn’t show the difference to be statistically significant. 
Socioeconomic level and urbanization were not found to be 
associated with higher likelihood of myoma.
Discussion
The association between menstrual pattern and myoma has 
been found to be inconsistent in the literature. Chen et al, in 
a large case–control study, found a menstrual cycle length 
of .30 days (OR: 1.6; 95% CI: 1.1–3.3), and menstrual 
bleeding for $6 days (OR: 1.4; 95% CI: 1.0–2.0) to be 
associated with developing myoma.8 In contrast , another 
study enrolling 73 women with myoma diagnosed after 
ultrasonography done on 341 Italian premenopausal women, 
didn’t find such an association.7 One main similarity between 
the study by Chen and ours was that they enrolled patients 
from those undergoing tubal ligation, and controls were 
selected from among women with no laparoscopic evidence 
of the history of fibroids. Similarly we also didn’t rule out 
the existence of possibly mild forms of myoma in the control 
group by ultrasonography. However, in the Italian study the 
outcome of interest was myoma diagnosed during screening 
by ultrasonography. So one theory explaining the contrast in 
Italian study is that menstrual pattern may not be associated 
with developing myoma but it may only explain symptomatic 
or larger myomas. This needs to be further clarified in future 
focused studies. Other than similarities in methodology and 
results of our study and that of Chen et al8 some differences 
also existed and need to be considered in interpreting the 
findings of the two studies. To prevent an ascertainment bias 
we limited our enrollment to surgically removed myomas. 
The age range in Chen’s study was limited to 17–44 years. 
Ours lacked such a limitation but our patients were older on 
average. We didn’t report age as a predictor because as age is 
a known factor for myoma, we preferred to match it in order 
to increase the statistical power of our analysis.
It seems that the association between length of menstrual 
cycle and myoma may not be linear. Chen et al8 explored the 
effect of longer cycles while our study looked at the role of 
shorter cycles, as in our study very few women were found 
with longer cycle lengths. Regarding the association found 
between menometrorrhagia and myoma in our study it should 
be taken into account that it can be interpreted as a symptom 
of myoma rather than a risk factor, because the temporality 
between these two conditions cannot be well clarified in a 
case–control study, considering the disease induction period 
and recall bias. In line with the findings of Wise and Chen, 
we didn’t find an association between myoma and use of oral 
contraceptive pills (OCPs).6,8   Contrary to Chen, the study by 
Wise et al,6 and our own findings, some studies have indicated 
that OCPs have a preventive role in uterine myoma.5,10–12 
However, Ross et al found such an effect only after at least 
10 years of OCP use.10 Interestingly, contrary to these studies, 
one study from Iran13 has found that OCP use may increase 
the likelihood of uterine myomas, although it seems that this 
finding may be due to ascertainment and selection bias as it 
studied self-reported myomas.   Depo-medroxyprogesterone 
acetate (DMPA) was found to be more frequent in the myoma 
group, but this was not statistically significant. The authors 
consider the lack of statistical significance to be due to the 
low statistical power of the study. Because DMPA is not a 
long-established FDA-approved drug for contraceptive use, 
and as those in our study were generally older, the overall 
frequency of DMPA use was low among our participants. 
Nevertheless, if this tendency becomes significant in larger 
scaled studies, a possible mechanism may be assumed based 
on the theory of estrogen dependence of uterine leiomyomas. 
The observed protective effect of DMPA against myomas 
may be explained by the hypo-estrogenic state induced by 
DMPA usage or by endometrial suppression induced by 
longer term use of DMPA.5,14,15
Table 2 Odds ratios for different cutoffs of menstrual cycle lengths 
for surgically treated myoma, and related confidence intervals
Menstrual  
cycle length
Odds ratio 95% Confidence 
interval
,22 days 3/8 1/34– 11/08
,23 days 3/3 1/21– 9/19
,24 days 3/18 1/8– 8/44
,25 days 2/42 1/23– 4/7
,26 days 1/85 0/97– 3/55International Journal of General Medicine
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Limitations
Surgically treated myoma was selected as the outcome in 
this study to prevent ascertainment bias and to discriminate 
between cases and controls with lower cost and effort. 
  Otherwise, due to the high prevalence of subclinical myo-
mas, the study would have been both expensive and more 
prone to bias. However, it should be taken into account that 
limiting the study to surgically treated myomas decreases the 
generalizability and limits drawing stronger conclusions. If a 
preventive factor is explored it may be due to the role of that 
factor in slowing the disease process rather than preventing 
it: in other words, it prevents the development of more severe 
myoma cases. This should be considered when interpreting 
the results of this study or other similar studies.
Conclusion
Menstrual cycle pattern is associated with the development of 
leiomyomas requiring surgical treatment. DMPA is assumed 
to have a role in preventing myomas, but due to the small 
sample size in this study, prospective trials are needed in 
the future.
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